Targeting the tumor vasculature with combretastatin A-4 disodium phosphate

Effects on radiation therapy

Lingyun Li, Amyn Mohammed Rojiani, Dietmar W. Siemann

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

Purpose: The aim of this study was to evaluate the antitumor efficacy of combretastatin A-4 disodium phosphate (combretastatin prodrug) in the rodent KHT sarcoma model either alone or in combination with radiation therapy. Methods: KHT tumors were grown in C3H/HeJ mice. Combretastatin A-4 prodrug was injected intraperitoneally at doses ranging from 10 to 100 mg/kg. Tumors were irradiated in unanesthetized mice using a 137Cs source. Tumor response to combretastatin A-4 prodrug was assessed by histological evaluations as well as an in vivo to in vitro cell survival assay. Results: Histological evaluation showed morphological damage of tumor cells within a few hours after drug treatment, followed by extensive central necrosis. Administering increasing doses of combretastatin A-4 prodrug to tumor- bearing mice resulted in a dose-dependent increase in cell killing irrespective of whether the tumors were irradiated or not. When combined with radiation, a 100 mg/kg dose of combretastatin A-4 prodrug reduced tumor cell survival 10-500-fold lower than that seen with radiation alone. Further, the shape of the cell survival curve observed following the combination therapy suggested that including combretastatin in the treatment had a major effect on the radiation-resistant hypoxic cell subpopulation associated with this tumor. Conclusion: The present results demonstrated that in the KHT sarcoma, combretastatin A-4 prodrug caused rapid vascular shutdown, a concentration- dependent direct cell killing, and effective enhancement of the antitumor effects of radiation therapy.

Original languageEnglish (US)
Pages (from-to)899-903
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume42
Issue number4
DOIs
StatePublished - Nov 1 1998
Externally publishedYes

Fingerprint

radiation therapy
phosphates
Prodrugs
Radiotherapy
tumors
Neoplasms
mice
dosage
Cell Survival
Sarcoma
radiation
cancer
Radiation
rodents
shutdowns
fosbretabulin
Inbred C3H Mouse
evaluation
necrosis
Radiation Effects

Keywords

  • Combretastatin
  • KHT sarcoma
  • Vascular targeting

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Targeting the tumor vasculature with combretastatin A-4 disodium phosphate : Effects on radiation therapy. / Li, Lingyun; Rojiani, Amyn Mohammed; Siemann, Dietmar W.

In: International Journal of Radiation Oncology Biology Physics, Vol. 42, No. 4, 01.11.1998, p. 899-903.

Research output: Contribution to journalArticle

@article{44f00929e0b34b4fbe7b50c7a72b8e5c,
title = "Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy",
abstract = "Purpose: The aim of this study was to evaluate the antitumor efficacy of combretastatin A-4 disodium phosphate (combretastatin prodrug) in the rodent KHT sarcoma model either alone or in combination with radiation therapy. Methods: KHT tumors were grown in C3H/HeJ mice. Combretastatin A-4 prodrug was injected intraperitoneally at doses ranging from 10 to 100 mg/kg. Tumors were irradiated in unanesthetized mice using a 137Cs source. Tumor response to combretastatin A-4 prodrug was assessed by histological evaluations as well as an in vivo to in vitro cell survival assay. Results: Histological evaluation showed morphological damage of tumor cells within a few hours after drug treatment, followed by extensive central necrosis. Administering increasing doses of combretastatin A-4 prodrug to tumor- bearing mice resulted in a dose-dependent increase in cell killing irrespective of whether the tumors were irradiated or not. When combined with radiation, a 100 mg/kg dose of combretastatin A-4 prodrug reduced tumor cell survival 10-500-fold lower than that seen with radiation alone. Further, the shape of the cell survival curve observed following the combination therapy suggested that including combretastatin in the treatment had a major effect on the radiation-resistant hypoxic cell subpopulation associated with this tumor. Conclusion: The present results demonstrated that in the KHT sarcoma, combretastatin A-4 prodrug caused rapid vascular shutdown, a concentration- dependent direct cell killing, and effective enhancement of the antitumor effects of radiation therapy.",
keywords = "Combretastatin, KHT sarcoma, Vascular targeting",
author = "Lingyun Li and Rojiani, {Amyn Mohammed} and Siemann, {Dietmar W.}",
year = "1998",
month = "11",
day = "1",
doi = "10.1016/S0360-3016(98)00320-4",
language = "English (US)",
volume = "42",
pages = "899--903",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Targeting the tumor vasculature with combretastatin A-4 disodium phosphate

T2 - Effects on radiation therapy

AU - Li, Lingyun

AU - Rojiani, Amyn Mohammed

AU - Siemann, Dietmar W.

PY - 1998/11/1

Y1 - 1998/11/1

N2 - Purpose: The aim of this study was to evaluate the antitumor efficacy of combretastatin A-4 disodium phosphate (combretastatin prodrug) in the rodent KHT sarcoma model either alone or in combination with radiation therapy. Methods: KHT tumors were grown in C3H/HeJ mice. Combretastatin A-4 prodrug was injected intraperitoneally at doses ranging from 10 to 100 mg/kg. Tumors were irradiated in unanesthetized mice using a 137Cs source. Tumor response to combretastatin A-4 prodrug was assessed by histological evaluations as well as an in vivo to in vitro cell survival assay. Results: Histological evaluation showed morphological damage of tumor cells within a few hours after drug treatment, followed by extensive central necrosis. Administering increasing doses of combretastatin A-4 prodrug to tumor- bearing mice resulted in a dose-dependent increase in cell killing irrespective of whether the tumors were irradiated or not. When combined with radiation, a 100 mg/kg dose of combretastatin A-4 prodrug reduced tumor cell survival 10-500-fold lower than that seen with radiation alone. Further, the shape of the cell survival curve observed following the combination therapy suggested that including combretastatin in the treatment had a major effect on the radiation-resistant hypoxic cell subpopulation associated with this tumor. Conclusion: The present results demonstrated that in the KHT sarcoma, combretastatin A-4 prodrug caused rapid vascular shutdown, a concentration- dependent direct cell killing, and effective enhancement of the antitumor effects of radiation therapy.

AB - Purpose: The aim of this study was to evaluate the antitumor efficacy of combretastatin A-4 disodium phosphate (combretastatin prodrug) in the rodent KHT sarcoma model either alone or in combination with radiation therapy. Methods: KHT tumors were grown in C3H/HeJ mice. Combretastatin A-4 prodrug was injected intraperitoneally at doses ranging from 10 to 100 mg/kg. Tumors were irradiated in unanesthetized mice using a 137Cs source. Tumor response to combretastatin A-4 prodrug was assessed by histological evaluations as well as an in vivo to in vitro cell survival assay. Results: Histological evaluation showed morphological damage of tumor cells within a few hours after drug treatment, followed by extensive central necrosis. Administering increasing doses of combretastatin A-4 prodrug to tumor- bearing mice resulted in a dose-dependent increase in cell killing irrespective of whether the tumors were irradiated or not. When combined with radiation, a 100 mg/kg dose of combretastatin A-4 prodrug reduced tumor cell survival 10-500-fold lower than that seen with radiation alone. Further, the shape of the cell survival curve observed following the combination therapy suggested that including combretastatin in the treatment had a major effect on the radiation-resistant hypoxic cell subpopulation associated with this tumor. Conclusion: The present results demonstrated that in the KHT sarcoma, combretastatin A-4 prodrug caused rapid vascular shutdown, a concentration- dependent direct cell killing, and effective enhancement of the antitumor effects of radiation therapy.

KW - Combretastatin

KW - KHT sarcoma

KW - Vascular targeting

UR - http://www.scopus.com/inward/record.url?scp=0031742231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031742231&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(98)00320-4

DO - 10.1016/S0360-3016(98)00320-4

M3 - Article

VL - 42

SP - 899

EP - 903

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -